System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Bram Verstockt is an expert in Gastroenterology at Universitair Ziekenhuis Leuven (Belgium). As of October 2026, ScienceLeadR ranks Bram Verstockt in the top 1% of experts worldwide for Colitis, Inflammatory Bowel Diseases and Gastroenteritis. Bram Verstockt has authored 561 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 14 of them ongoing. SLR score: 2,598 (community average: 125). How the SLR is computed.

LeadR Profile

Bram Verstockt Universitair Ziekenhuis Leuven Belgium
2 598 ScienceLeadR Reputation 2598

Unlock

Register Login
Network Map

Gastroenterology

Subspecialties: Hepatology - Pharmacy - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2013 - 2026
Source: PubMed

Universitair Ziekenhuis Leuven

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 561

Citations

Citations: 9 040 1st author: 91 Last author: 63 Unique author: 4

Main journals

J Crohns Colitis 271
Gastroenterology 101
Clin Gastroenterol Hepatol 17
Inflamm Bowel Dis 17
Aliment Pharmacol Ther 10

Best Journals

Lancet Gastroenterol Hepatol 6
Gastroenterology 5
Nat Rev Gastroenterol Hepatol 5

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Shared decision making in inflammatory bowel disease: a qualitative study with patients, gastroenterologists, and nurses.
PMID 42907825 — nurses, decision making, shared, communication, decision making, inflammatory bowel diseases, health services research, gastroenterologists		BMC Health Serv Res20260
Emulsifier Intake in Healthy Controls and Patients with Inflammatory Bowel Disease: A Cross-Sectional Comparative Study with Longitudinal Follow-Up of Long-Term Outcomes.
PMID 42892326 — food, inflammatory bowel diseases, food, processed		J Acad Nutr Diet20260
Distinct intestinal eosinophil subsets in ulcerative colitis and their modulation by advanced inflammatory bowel disease therapies.
PMID 42786564 — cells, colitis, colon, eosinophils, biomarkers, inflammatory bowel diseases, therapeutics, tissues, colitis, ulcerative		J Crohns Colitis20260
REG3α is a Predictive Biomarker of Complicated Disease from Preclinical through Established Crohn's Disease.
PMID 42685961 — cells, autophagy, serum, crohn disease, digestive system diseases, paneth cells, biomarkers, diagnosis		Clin Gastroenterol Hepatol20260
Positioning Guselkumab in The Treatment Algorithm for Ulcerative Colitis.
PMID 42609214 — interleukin-23, colitis, safety, algorithms, therapeutics, colitis, ulcerative		J Inflamm Res20260

Clinical Studies 25

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

Phase 2 11
N/A 5
Phase 3 4
Phase 1 2
Phase 4 2
Phase 2/Phase 3 1

By status:

Recruiting 10
Completed 6
Not yet recruiting 3
Unknown 3
Active not recruiting 2
Terminated 1

By type:

Interventional 24
Observational 1

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 1
multicentric5to9 0
multicentricup10 19

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

14 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Efficacy and Safety of JNJ 78934804 in Participants With Moderately to Severely Active Crohn s Disease
2026-525922-39-00 — safety, crohn disease		Phase 3Not yet recruiting2026
Efficacy and Safety of JNJ 78934804 in Participants with Moderately to Severely Active Ulcerative Colitis
2026-525923-26-00 — colitis, safety, colitis, ulcerative		Phase 3Recruiting2026
A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease
2025-522001-38-00 — colitis, safety, crohn disease, multiple chronic conditions, inflammatory bowel diseases, therapeutics, colitis, ulcerative, pharmacokinetics		Phase 2Recruiting2026
Crohn s Head to Head Assessing Risankizumab Versus Guselkumab for One Year
2025-521590-13-00 — safety, crohn disease, therapeutics, head		Phase 3Recruiting2026
An Early Stage Study in Multiple Clinics of how Afimkibart May Affect the Body s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis
2025-524060-38-00 — cytochrome p-450 enzyme system, colitis, cytochromes, enzymes, colitis, ulcerative		Phase 1Not yet recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS